Supplementary Figure S3 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

Ashley V. DiMarco; Mirunalini Ravichandran; Jeff Lau; Anthony Lima; Jennifer A. Lacap; Pablo Saenz-Lopez Larrocha; Eva Lin; Julie Weng; Luca Gerosa; Thomas Hunsaker; Yang Xiao; Monika Miś; Charles Havnar; Wennie Chen; Kai Barck; Klára Tótpál; Oded Foreman; Nicole M. Sodir; Mark Merchant; Danilo Maddalo

doi:10.1158/0008-5472.30029570

Key Points

RIT1 mutations drive tumorigenesis and therapy resistance in lung adenocarcinoma, impacting treatment efficacy.
The human RIT1 cell line NCI-H2110 shows sensitivity to multiple targeted agents, with promising combination results.
In vitro and in vivo analyses demonstrate that migoprotafib, belvarafenib, and cobimetinib are effective against RIT1-driven tumors.
These findings highlight the need for tailored therapies in lung adenocarcinoma subtypes driven by specific mutations.

Implication

Supplementary figure reveals RIT1 role in lung adenocarcinoma tumorigenesis and resistance to targeted therapy, suggesting new treatment strategies.

Abstract

Supplementary Figure S3: Human RIT1 cell line, NCI-H2110, is sensitive to migoprotafib, belvarafenib, cobimetinib as single agent and in combination in vitro and in vivo.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

DiMarco et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd02ae2 https://doi.org/10.1158/0008-5472.30029570

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S3 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S3 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading